Pharmacotherapy of type 2 diabetes: An update

被引：153

作者：

Upadhyay, Jagriti ^{[1
,2
]}

Polyzos, Stergios A. ^{[3
]}

Perakakis, Nikolaos ^{[2
,4
,5
]}

Thakkar, Bindiya ^{[1
]}

Paschou, Stavroula A. ^{[2
]}

Katsiki, Niki ^{[6
]}

Underwood, Patricia ^{[1
]}

Park, Kyung-Hee ^{[7
]}

Seufert, Jochen ^{[4
,5
]}

Kang, Eun Seok ^{[8
]}

Sternthal, Elliot ^{[1
]}

Karagiannis, Asterios ^{[3
]}

Mantzoros, Christos S. ^{[1
,2
]}

机构：

[1] Boston VA Healthcare Syst, Sect Endocrinol Diabet & Metab, Boston, MA 02130 USA

[2] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Endocrinol Diabet & Metab, Dept Internal Med, Boston, MA 02115 USA

[3] Aristotle Univ Thessaloniki, Med Sch, Dept Pharmacol 1, Thessaloniki, Greece

[4] Univ Hosp Freiburg, Div Endocrinol, Dept Internal Med 2, Freiburg, Germany

[5] Univ Hosp Freiburg, Div Diabetol, Dept Internal Med 2, Freiburg, Germany

[6] Aristotle Univ Thessaloniki, Med Sch, Hippocrat Hosp, Propedeut Dept Internal Med 2, Thessaloniki, Greece

[7] Hallym Univ Sacred Heart Hosp, Dept Family Med, Gyeonggi Do, South Korea

[8] Yonsei Univ, Coll Med, Div Endocrinol & Metab, Dept Internal Med, Seoul, South Korea

来源：

METABOLISM-CLINICAL AND EXPERIMENTAL | 2018年 / 78卷

关键词：

Algorithm; Goals pharmacotherapy; Personalized therapy; Type; 2; diabetes; GLUCAGON-LIKE PEPTIDE-1; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; IMPROVES GLYCEMIC CONTROL; CARDIOVASCULAR RISK-FACTORS; PLACEBO-CONTROLLED TRIAL; TWICE-DAILY EXENATIDE; HUMAN GLP-1 ANALOG; BETA-CELL FUNCTION; GLUCOSE COTRANSPORTER-2 INHIBITORS; PREVIOUS MYOCARDIAL-INFARCTION;

D O I：

10.1016/j.metabol.2017.08.010

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Type 2 diabetes (T2DM) is a leading cause of morbidity and mortality worldwide and a major economic burden. The prevalence of T2DM is rising, suggesting more effective prevention and treatment strategies are necessary. The aim of this narrative review is to summarize the pharmacologic treatment options available for patients with T2DM. Each therapeutic class is presented in detail, outlining medication effects, side effects, glycemic control, effect on weight, indications and contraindications, and use in selected populations (heart failure, renal insufficiency, obesity and the elderly). We also present representative cost for each antidiabetic category. Then, we provide an individualized guide for initiation and intensification of treatment and discuss the considerations and rationale for an individualized glycemic goal. (C) 2017 Elsevier Inc. All rights reserved.

引用

页码：13 / 42

页数：30

共 358 条

[81] Patterns of Medication Initiation in Newly Diagnosed Diabetes Mellitus: Quality and Cost Implications [J].

Desai, Nihar R. ;

Shrank, William H. ;

Fischer, Michael A. ;

Avorn, Jerry ;

Liberman, Joshua N. ;

Schneeweiss, Sebastian ;

Pakes, Juliana ;

Brennan, Troyen A. ;

Choudhry, Niteesh K. .

AMERICAN JOURNAL OF MEDICINE, 2012, 125 (03) :302.e1-302.e7

[82] Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin [J].

Devineni, D. ;

Morrow, L. ;

Hompesch, M. ;

Skee, D. ;

Vandebosch, A. ;

Murphy, J. ;

Ways, K. ;

Schwartz, S. .

DIABETES OBESITY & METABOLISM, 2012, 14 (06) :539-545

[83] Refining basal insulin therapy: what have we learned in the age of analogues? [J].

DeVries, J. H. ;

Nattrass, M. ;

Pieber, T. R. .

DIABETES-METABOLISM RESEARCH AND REVIEWS, 2007, 23 (06) :441-454

[84] Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes [J].

Diamant, Michaela ;

Nauck, Michael A. ;

Shaginian, Rimma ;

Malone, James K. ;

Cleall, Simon ;

Reaney, Matthew ;

de Vries, Danielle ;

Hoogwerf, Byron J. ;

MacConell, Leigh ;

Wolffenbuttel, Bruce H. R. .

DIABETES CARE, 2014, 37 (10) :2763-2773

[85] Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial [J].

Dormandy, JA ;

Charbonnel, B ;

Eckland, DJA ;

Erdmann, E ;

Massi-Benedetti, M ;

Kmoules, IK ;

Skene, AM ;

Tan, MH ;

Lefébvre, PJ ;

Murray, GD ;

Standl, E ;

Wilcox, RG ;

Wlhelmsen, L ;

Betteridge, J ;

Birkeland, K ;

Golay, A ;

Heine, RJ ;

Korányi, L ;

Laakso, M ;

Mokán, M ;

Norkus, A ;

Pirags, V ;

Podar, T ;

Scheen, A ;

Scherbaum, W ;

Schernthaner, G ;

Schmitz, O ;

Skrha, J ;

Smith, U ;

Taton, J .

LANCET, 2005, 366 (9493) :1279-1289

[86] Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes An Overview of Data from PROactive [J].

Dormandy, John ;

Bhattacharya, Mondira ;

de Bruyn, Anne-Ruth van Troostenburg .

DRUG SAFETY, 2009, 32 (03) :187-202

[87] DOUBLE-BLIND EVALUATION OF EFFICACY AND TOLERABILITY OF METFORMIN IN NIDDM [J].

DORNAN, TL ;

HELLER, SR ;

PECK, GM ;

TATTERSALL, RB .

DIABETES CARE, 1991, 14 (04) :342-344

[88] Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study [J].

Drucker, Daniel J. ;

Buse, John B. ;

Taylor, Kristin ;

Kendall, David M. ;

Trautmann, Michael ;

Zhuang, Dangliang ;

Porter, Lisa .

LANCET, 2008, 372 (9645) :1240-1250

[89] The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes [J].

Drucker, Daniel J. ;

Nauck, Michael A. .

LANCET, 2006, 368 (9548) :1696-1705

[90] Enhancing incretin action for the treatment of type 2 diabetes [J].

Drucker, DJ .

DIABETES CARE, 2003, 26 (10) :2929-2940

← 4 5 6 7 8 9 10 11 12 13 →